Last updated on May 2018

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC


Brief description of study

This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.

Detailed Study Description

The study has 2 parts:

Part A (Dose-Escalation Cohorts): Consecutive cohorts of patients will receive escalating doses of oral palbociclib in combination with intravenous nab-P in 28-day cycles, in order to estimate the MTD(s) of the combination. The starting doses will be 75 mg palbociclib, and 100 mg/m2 nab-P. The observation period for dose-limiting toxicities (DLTs) will be from Day 1 to Day 28. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of palbociclib and nab-P will also be assessed. Up to approximately 30 patients will be enrolled. The criteria for dose escalation will be based on a modified toxicity probability interval (mTPI) method.

Part B [MTD Expansion Cohort(s)]: When the MTD(s) of palbociclib plus nab-P has been estimated with confidence, enrollment will proceed into 1 or 2 MTD expansion cohort(s) of up to 20 patients each at the MTD(s). The objective of the MTD expansion cohort(s) will be to provide additional information on safety, tolerability, biomarkers, PD activity, and PK/PD relationship for the combination regimen in order to determine the RP2D. The MTD expansion cohort(s) will only enroll patients who have not received previous treatment for their metastatic disease in order to evaluate preliminary activity of the combination in the target patient population.

All patients (in Part A and B) will receive nab-P intravenously once weekly for 3 weeks out of each 28-day cycle. Palbociclib oral dosing will be once daily on Days 1-21 of each 28-day cycle. To allow for PK evaluation of nab-P administered alone, nab-P will be administered on Day -2 for Cycle 1 only. Subsequent cycles will administer both nab-P and palbociclib on Day

  1. Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and safety data.

Patients will be treated as long as they are clinically benefiting from investigational product without unacceptable toxicity, objective disease progression, or withdrawal of consent. A modified visit schedule will be implemented for patients who are on investigational product for more than 2 years.

Clinical Study Identifier: NCT02501902

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale, AZ United States
  Connect »

Pfizer CT.gov Call Center

Virginia G. Piper Cancer Pharmacy
Scottsdale, AZ United States
  Connect »

Pfizer CT.gov Call Center

UC San Diego Medical Center - La Jolla (Thornton Hospital)
La Jolla, CA United States
  Connect »

Pfizer CT.gov Call Center

UC San Diego Moores Cancer Center
La Jolla, CA United States
  Connect »

Pfizer CT.gov Call Center

UC San Diego Medical Center - Hillcrest
San Diego, CA United States
  Connect »

Pfizer CT.gov Call Center

Drug Shipment Address: Anschutz Cancer Pavilion
Aurora, CO United States
  Connect »

Pfizer CT.gov Call Center

University of Colorado Cancer Center
Aurora, CO United States
  Connect »

Pfizer CT.gov Call Center

University of Colorado Denver, CTO (CTRC)
Aurora, CO United States
  Connect »

Pfizer CT.gov Call Center

Oncology Investigational Drug Services (Drug Shipment Only)
Baltimore, MD United States
  Connect »

Pfizer CT.gov Call Center

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD United States
  Connect »

Pfizer CT.gov Call Center

Johns Hopkins Hospital
Baltimore, MD United States
  Connect »

Pfizer CT.gov Call Center

Beth Israel Deaconess Medical Center
Boston, MA United States
  Connect »

Pfizer CT.gov Call Center

Siteman Cancer Center - West County
Creve Coeur, MO United States
  Connect »

Pfizer CT.gov Call Center

Barnes-Jewish Hospital
Saint Louis, MO United States
  Connect »

Pfizer CT.gov Call Center

Washington University Infusion Center Pharmacy
Saint Louis, MO United States
  Connect »

Pfizer CT.gov Call Center

Washington University School of Medicine
Saint Louis, MO United States
  Connect »

Pfizer CT.gov Call Center

Siteman Cancer Center - South County
Saint Louis, MO United States
  Connect »

Pfizer CT.gov Call Center

Siteman Cancer Center
Saint Peters, MO United States
  Connect »

Pfizer CT.gov Call Center

University of Utah, Huntsman Cancer Hospital
Salt Lake City, UT United States
  Connect »

Pfizer CT.gov Call Center

University of Utah, Huntsman Cancer Institute
Salt Lake City, UT United States
  Connect »

Pfizer CT.gov Call Center

Hospital Universitario de Fuenlabrada. Unidad de Farmacia (Only Drug Shipment)
Fuenlabrada, Spain
  Connect »

Pfizer CT.gov Call Center

Hospital Universitario Fuenlabrada
Fuenlabrada, Spain
  Connect »

Pfizer CT.gov Call Center

Hospital Universitari Vall D'Hebron
Barcelona, Spain
  Connect »

Pfizer CT.gov Call Center

Hospital Universitario 12 de Octubre Servicio de Farmacia
Madrid, Spain
  Connect »

Pfizer CT.gov Call Center

Hospital Universitario 12 de Octubre
Madrid, Spain
  Connect »

Pfizer CT.gov Call Center

UC San Diego Moores Cancer Center - Investigational Drug Services
La Jolla, CA United States
  Connect »

Pfizer CT.gov Call Center

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, CO United States
  Connect »

Pfizer CT.gov Call Center

University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, CO United States
  Connect »

Pfizer CT.gov Call Center

UCSD Medical Center - Encinitas
Encinitas, CA United States
  Connect »

Pfizer CT.gov Call Center

UCSD Medical Center - Vista
Vista, CA United States
  Connect »